BDTX (Black Diamond Therapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics OCF Margin %?

Black Diamond Therapeutics BDTX +0.59% 38 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BDTX with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Black Diamond Therapeutics ranks better than 52.66% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Black Diamond Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-10.23 Mil. Black Diamond Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Black Diamond Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Black Diamond Therapeutics's current OCF Yield % is -34.73%.

The historical rank and industry rank for Black Diamond Therapeutics's OCF Margin % or its related term are showing as below:

BDTX' s OCF Margin % Range Over the Past 10 Years
Min: 42.31   Med: 42.31   Max: 42.31
Current: -48.61

During the past 9 years, the highest OCF Margin % of Black Diamond Therapeutics was 42.31%. The lowest was 42.31%. And the median was 42.31%.

BDTX's OCF Margin % is ranked better than
52.66% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs BDTX: -48.61

Black Diamond Therapeutics OCF Margin % Related Terms

Black Diamond Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics OCF Margin % Chart

Black Diamond Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 42.31

Black Diamond Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.30 0.00 0.00 0.00 0.00

BDTX vs GUTS, ALPS, ONCY: OCF Margin % Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's OCF Margin % falls into.


BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Black Diamond Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=29.614/70
=42.31 %

Black Diamond Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-10.232/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Black Diamond Therapeutics (BDTX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Black Diamond Therapeutics and its competitors. Over the past decade, Black Diamond Therapeutics' OCF Margin % has ranged from 42.31 to 42.31. According to the industry distribution chart, Black Diamond Therapeutics ranks #454 out of 959 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Black Diamond Therapeutics' OCF Margin % too high?
Black Diamond Therapeutics' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 42.31 to a high of 42.31. Based on the distribution chart, Black Diamond Therapeutics ranks #454 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Black Diamond Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' OCF Margin % compare to GUTS and ALPS?
According to the Biotechnology industry distribution chart, Black Diamond Therapeutics ranks #454 out of 959 companies for OCF Margin %. This puts Black Diamond Therapeutics in the upper half of its industry. Historically, Black Diamond Therapeutics' own OCF Margin % has ranged from 42.31 to 42.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Black Diamond Therapeutics' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price